Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S, OLYMPIA 2 Investigators

Open source

DOI: 10.1056/nejmoa2301333
Published: 2023 Oct 26
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2301333,
  title = {Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.},
  author = {Kwatra SG and Yosipovitch G and Legat FJ and Reich A and Paul C and Simon D and Naldi L and Lynde C and De Bruin-Weller MS and Nahm WK and Sauder M and Gharib R and Barbarot S and Szepietowski JC and Conrad C and Fleischer A and Laquer VT and Misery L and Serra-Baldrich E and Lapeere H and Ahmad F and Jabbar Lopez ZK and Piketty C and Ständer S and OLYMPIA 2 Investigators},
  year = {2023},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2301333},
  url = {https://doi.org/10.1056/nejmoa2301333}
}

RIS

TY  - JOUR
TI  - Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
AU  - Kwatra SG
AU  - Yosipovitch G
AU  - Legat FJ
AU  - Reich A
AU  - Paul C
AU  - Simon D
AU  - Naldi L
AU  - Lynde C
AU  - De Bruin-Weller MS
AU  - Nahm WK
AU  - Sauder M
AU  - Gharib R
AU  - Barbarot S
AU  - Szepietowski JC
AU  - Conrad C
AU  - Fleischer A
AU  - Laquer VT
AU  - Misery L
AU  - Serra-Baldrich E
AU  - Lapeere H
AU  - Ahmad F
AU  - Jabbar Lopez ZK
AU  - Piketty C
AU  - Ständer S
AU  - OLYMPIA 2 Investigators
PY  - 2023
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2301333
UR  - https://doi.org/10.1056/nejmoa2301333
ER  -

APA

SG, K., G, Y., FJ, L., A, R., C, P., D, S., L, N., C, L., MS, D. B., WK, N., M, S., R, G., S, B., JC, S., C, C., A, F., VT, L., L, M., E, S., H, L., F, A., ZK, J. L., C, P., S, S., & Investigators, O. 2. (2023). Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2301333

Source records

pubmed · retrieved 2026-09-26T13:57:56.928Z